Category

Archives

EGFR

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

27 views | Oct 15 2021

Laura Díaz-Gil et al. thought that the identification of trastuzumab response biomarkers might be used to select patients particularly sensitive to facilitate the use of trastuzumab-based therapies and refine follow-up guidelines in patients with HER2+ tumors. [Read the Full Post]

An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy

110 views | Sep 19 2021

Erika Yan Wang et al. found multifaceted cardioprotective effects of relaxin in restoring contractile function and reducing fibrotic remodeling. [Read the Full Post]

Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial

90 views | Sep 17 2021

Krishna T Patel et al. suggested a possible therapeutic role for Src/Fyn kinase inhibitors in AUD risk. [Read the Full Post]

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

132 views | Sep 07 2021

Long-Sheng Chang et al. demonstrated the power of the de novo unbiased approach for drug discovery and represented a major step forward in the advancement of therapeutics for the treatment of NF2 related malignancies. [Read the Full Post]

MiR-221 confers lapatinib resistance by negatively regulating p27 kip1 in HER2-positive breast cancer

195 views | Aug 16 2021

Thanh Kieu Huynh et al. suggested Src inhibition as a potential strategy to overcome lapatinib resistance. [Read the Full Post]

Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

153 views | Aug 01 2021

Chi-Tai Yeh et al. suggested that BTK mediated stemness and EMT properties, and inhibition of BTK potentiated the effect of Gefitinib and Osimertinib in NSCLC cells resistant to TKI. [Read the Full Post]

XHL11, a novel selective EGFR inhibitor, overcomes EGFR T790M-mediated resistance in non-small cell lung cancer

121 views | Jul 07 2021

Yi Li et al. thought that XHL11 might be developed as a promising EGFR TKI for the therapeutic use of NSCLC patients. [Read the Full Post]

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report

130 views | Jun 16 2021

Kota Sasaki et al. thought that lorlatinib could be a treatment option for patients with ALK-positive NSCLC showing carcinomatous meningitis, poor PS, and dysphagia upon failure of other ALK inhibitor-based treatments. [Read the Full Post]

Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib

170 views | Jun 08 2021

Muneerah M Aleissa et al. found that concomitant gilteritinib and triazole therapy was feasible and was not associated with clinically meaningful increase in gilteritinib-related AEs. [Read the Full Post]

Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database

156 views | Jun 02 2021

Misaki Inoue et al. revealed several drugs associated with a high risk for CIPN development. [Read the Full Post]